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Immunoscore and Microbiome in 
Colorectal Cancer: What’s New?
Filipa Macedo, Nuno Bonito, Adhemar Longatto-Filho 
and Sandra F. Martins
Abstract
Colorectal cancer (CRC) is the third most commonly diagnosed malignancy 
and the fourth leading cause of cancer death in the world, accounting for about 1.4 
million new cases and almost 700,000 deaths in 2012. The clinical outcome and the 
tumor progression are now considered the result of a balance between the invasive-
ness of the tumor and the immune response of the patient against the tumor. The 
immune system has the ability to control and shape cancer through a mechanism 
called immunoediting, which include elimination, equilibrium, and escape. The 
consensus Immunoscore is a scoring system that outlines the density of CD3+ and 
CD8+ T-cell effectors existent in the tumor and its invasive margin. The pre-existing 
intra-tumoral immunity could be enhanced and activated by immunotherapy. 
Immunoscore could be a good prognostic marker, by identifying patients at high 
risk of tumor recurrence and stratifying patients who could benefit from adjuvant 
therapies. Human surfaces and cavities are populated by numerous microbial com-
munities, and they play an indispensable role in human health, as they interact with 
the immune system. The authors made a literature revision concerning the role of 
Immunoscore and microbiome in colorectal cancer.
Keywords: colorectal cancer, Immunoscore, microbiome, diet, CD3+ T cell, 
CD8+ T cell
1. Colorectal cancer facts
Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and 
the fourth leading cause of cancer death in the world, accounting for about 1.4 mil-
lion new cases and almost 700,000 deaths in 2012 [1]. In Portugal, the incidence of 
CRC is 42.80 new cases for 100,000 habitants with a mortality rate of 26.6 [2]. The 
distribution of CRC burden varies widely around the world, with more than two-
thirds of all cases and about 60% of all deaths occurring in developed countries. 
The global burden of CRC is expected to increase by 60% to more than 2.2 million 
new cases and 1.1 million cancer deaths by 2030 [1]. The lifetime risk of developing 
colorectal cancer is about 6%, which increased fourfold if there is a family history 
of CRC.
The multistep models of CRC tumorigenesis postulate an adenoma-carcinoma 
sequence as the main pathway to develop a cancer. It tells us that CRC arises from 
a benign precursor polyp that became dysplastic and invasive due to accumulative 
mutations [3].
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There are several risk factors for CRC: inherited predisposition (the involve-
ment of at least one first-degree relative doubles the risk, and the risk is even 
higher if the affected case was prior to the age of 60), obesity, total caloric intake, 
red meat, sedentary lifestyle and physical inactivity, alcohol consumption, and 
prolonged cigarette smoking. A low incidence of CRC is associated with high-fiber 
diet (it dilutes fecal carcinogens, decreases colon transit time, and generates a 
favorable luminal environment), fruits and vegetables, aspirin, and nonsteroidal 
anti-inflammatory drugs [4].
An anatomic shift is being observed once the incidence of right-sided or proxi-
mal cancer is rising. This shift is due to increased longevity, a response to luminal 
carcinogens and genetic defects like defects in mismatch repair genes with result-
ing microsatellite instability (MSI) in proximal colon cancers and chromosomal 
instability pathway (CIN) in left-sided colon cancer.
Since 2015, there are five consensus molecular subtypes (CMS) of CRC [5]. The 
CMS1 is the MSI-immune and accounts for 14% of the cancers. This subtype is 
characterized by proximal colon locations, high BRAF V600E mutation rate, hyper-
methylation of CpG islands which causes loss of tumor suppressor function, an 
association with an impaired DNA mismatch repair (MMR) system, an infiltration 
of immunogenic lymphocytes in the microenvironment, and MSI. MSI cancers are 
also considered “hypermutated” with approximately 47 mutations per 106 bases, 
compared to microsatellite stable (MSS or CMS2) tumors which average 2.8/106 
bases. The clinical implications of this subtype are that early stage MSI tumors 
(most CMS1 cancers) have better prognosis than MSS cancers. Stage II cancers with 
MSI have a low recurrence rate and thus are generally not considered for adjuvant 
chemotherapy. Patients with stage III MSI tumors do not benefit from fluorouracil 
monotherapy but are responsive to combination fluorouracil, leucovorin, and 
oxaliplatin (FOLFOX) adjuvant chemotherapy. CMS1 tumors have a favorable 
outcome when detected before disease dissemination. In part, the good prognosis 
may be linked to the presence of specific T-cell populations: CD8+ cytotoxic T 
lymphocytes, CD4+ activated type 1 T helper cells (Th1), and natural killer cells. 
However, CMS1 tumors were associated with worse survival after relapse [5, 6]. The 
CMS2 is the canonical subtype and accounts for 37% of the cancers. This subtype 
is characterized by a low mutation rate. Five-year overall survival for all stages of 
CMS2 is the highest, and it has the highest survival rate after relapse. Additionally, 
CMS2 cancers were more commonly left-sided lesions (59%) [5, 6]. The CMS3 is 
the metabolic subtype and accounts for 13% of the cancers. This subtype is char-
acterized by RAS mutations (68% of the cancers) which predict poor response to 
epidermal growth factor receptor (EGFR) monoclonal antibodies (e.g., cetuximab) 
[5, 6]. The CMS4 is the mesenchymal subtype and accounts for 23% of the cancers. 
This subtype is characterized by very high pro-inflammatory microenvironment. 
Additionally, they exhibit extremely low levels of hypermutation and are MSS 
status. CMS4 cancers, often diagnosed at advanced stages, have a poor prognosis 
with the worst 5-year overall survival (62%) and relapse-free survival (60%) of any 
molecular subtype. Although standard adjuvant therapy (FOLFOX) for stage III is 
recommended, CMS4 cancers show no benefit from systemic adjuvant treatments.
For metastatic disease, CMS4 cancers are resistant to anti-EGFR therapy, inde-
pendent of RAS mutation status. Anti-angiogenesis therapies such as bevacizumab 
are standard additions for stage IV disease [5, 6]. Finally, the last subtype is the 
mixed features and accounts for 13% of the cancers [5, 6].
There are four stages of colon cancer considering their size, number of lymph 
nodes, and distant metastasis (TNM). Stage 1 comprehends the T1 and T2 tumors 
(extension to submucosa and muscularis propria), and the treatment is only 
chirurgical. Stage 2 englobes the T3 and T4 tumors (subserosa, invasion of visceral 
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peritoneum and organs), and the treatment depends if the patient is considered 
of low or high risk. The low-risk patients only do surgery; the high-risk patients 
have 1 of the following criteria: less than 12 lymph nodes resected; low differenti-
ated tumor; vascular, lymphatic, or perineural invasion; perforation or intestinal 
obstruction; T4 tumor; and MSS status. The high-risk stage II and stage III (with 
lymph nodes positive for disease) patients are submitted to adjuvant chemotherapy 
after surgery with fluoropirimidine and oxaliplatin. Stage IV cancer is a metastatic 
disease, which could be resected if feasible or controlled with chemotherapy.
2. What is an Immunoscore?
The clinical outcome and the tumor progression are now considered the result 
of a balance between the invasiveness of the tumor and the immune response of the 
patient against the tumor. The immune system has the ability to control and shape 
cancer through a mechanism called immunoediting, which include elimination, 
equilibrium, and escape [7].
It was already shown that the strength of the in situ adaptive immune reaction 
is strongly correlated with time to recurrence and overall survival of CRC [8]. This 
in situ immune cell infiltration in cancer, called high density of tumor-infiltrating 
lymphocytes (TIL), is associated with a favorable prognostic effect [8]. Once cancer 
becomes clinically detectable, the adaptive immune response plays a critical role 
in preventing tumor recurrence, metastization, and clinical outcome. A protective 
response is maintained by the ability of memory T cells to recall previously encoun-
tered antigens [9]. Concerning to regulatory T cells (Tregs), Sinicrope et al. showed 
an association between a low CD3+/FoxP3+ cell ratio and shorter survival [10], but 
Salama et al. showed the opposite, a high Treg density in the tumor was associated 
with improved survival [11]. Regarding TH17 and TH1 immune response, TH17 is 
associated with poor prognosis [12], and TH1 is associated with prolonged disease-
free survival [13].
The consensus Immunoscore is a scoring system that outlines the density of 
CD3+ and CD8+ T-cell effectors existent in the tumor and its invasive margin. The 
pre-existing intra-tumoral immunity could be enhanced and activated by immuno-
therapy. Immunoscore could be a good prognostic marker, by identifying patients 
at high risk of tumor recurrence and stratifying patients who could benefit from 
adjuvant therapies [14]. This score is based in the numeration of two lymphocyte 
populations (CD3/CD45RO, CD3/CD8 or CD8/CD45RO), in density (Cells/mm2) 
and the location (in the core of the tumor or in the invasive margin) [15]. The score 
ranges from Immunoscore 0 (I0) when low densities of both cell types are found in 
both regions to Immunoscore 4 (I4) when high densities are found in both regions.
3. Clinical applications of Immunoscore
Immunoscore has been tested to be a prognostic marker that surpasses the TNM 
staging. Pages et al. concluded that patients with high Immunoscore had the lowest 
risk of recurrence and longest survival. In his study, only 5% of the patients with 
high Immunoscore had a recurrence at 3 years, 87% of the patients reached the over-
all survival at 3 years, and 82% of the patients reached 5-year overall survival [14].
There is a possible association between MSI status and immune cell infiltrates. 
MSI-high tumors have intraepithelial T cells due to expression of neo-antigens on 
the cell surface, and this could be the reason why this kind of tumors had better 
prognosis [15].
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Comparing to the American Joint Committee on Cancer/Union for 
International Cancer Control (AJCC/UICC) TNM classification system, the 
Immunoscore classification seems to be superior as prognostic tool. For all patients 
with CRC stages I/II/III, multivariate Cox analysis revealed that the immune 
criteria remained highly associated with prognosis [16]. Wirta et al. concluded that 
a lower Immunoscore was associated with increasing AJCC/UICC stage, as well as 
with increasing T stage, presence of lymph node, distant metastasis, and perineu-
ral or lymphovascular invasion [17].
One day the classification of cancer will have a new component, TNM-I 
(immune).
Additionally, Immunoscore can predict the response to treatment and could be 
a biomarker that helps clinicians to decide what patients must have chemotherapy. 
Morris et al. concluded that high TIL is predictive of response to chemotherapy with 
5-fluorouracil [18], and Viaud et al. revealed that cyclophosphamide induces a TH17 
and TH1 antitumor response, making the tumors resistant to this chemotherapy [19].
4. What is a microbiome?
Human surfaces and cavities are populated by numerous microbial communi-
ties, like bacteria or fungi, which form a complex interactive network between 
themselves and the host. The gastrointestinal microbiota is estimated to contain 
over 1000 different phylotypes with a microbial gene catalog of 3.3 million genes 
[20], but it can be divided into four main categories: Firmicutes, Bacteroides, 
Actinobacteria, and Proteobacteria [21]. These agents play an indispensable role 
in human health, as they interact with the immune system, maintain epithelial 
homeostasis, metabolize indigestible polysaccharides, modulate the intestinal 
motility, regulate the luminal pH, and exclude potential pathogens from the human 
gut [22]. The disruption of intestinal microbial equilibrium has the capacity to alter 
the homeostatic network, thereby eliciting deleterious host responses as observed 
in inflammatory bowel disease and CRC. The dysbiosis refers to perturbations in 
microbial populations [23].
Wong et al. proved that intestinal microbiota has an important role in CRC 
carcinogenesis. Mice fed with stool from patients with CRC had a higher rate of 
high-grade dysplasia than the mice fed with stool from healthy controls, suggest-
ing that human commensals may not be tumorigenic [24]. Bacteria may contribute 
to CRC in several ways: they can break the mucus layer and adhere to intestinal 
mucosa and deliver virulent proteins and molecules that will initiate oncogenic 
signaling in epithelial cells. As so, they can induce DNA damage leading to tumor 
initiation. On the other hand, bacteria can trigger procarcinogenic signaling and 
inflammatory microenvironment, such as IL-17 production or excessive Wnt or 
Stat3 signaling [25].
Some studies have identified several bacteria that can promote carcinogenesis 
by different mechanisms: Escherichia coli can cause direct DNA damage such as 
crosslinks and double-strand breaks due to the colibactin toxin produced by it 
[26], Fusobacterium nucleatum can produce FadA adhesin to modulate E-cadherin/
beta-catenin signaling [27], Peptostreptococcus anaerobius can induce cell prolifera-
tion through toll-like receptor 2 and toll-like receptor 4 pathways [28], Bacteroides 
fragilis produces a toxin that activates Wnt and NF-kB pathways which induce a 
pro-inflammatory state [29], and Streptococcus gallolyticus induces tumor growth 
through enhancement of inflammatory signals including cyclooxygenase-2 [30].
Xu et al. compared normal tissue with adenomas and adenocarcinomas and 
concluded that the microorganisms are different between the three entities. In the 
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cancer group, 20 biomarkers were identified: Bulleidia, Catonella, Clostridium, 
Dialister, Granulicatella, Lactobacillus, Mogibacterium, Oscillospira, Parvimonas, 
Peptostreptococcus, Streptococcus, Odoribacter, Paraprevotella, Porphyromonas, 
Prevotella, Fusobacterium, Leptotrichia, Campylobacter, Desulfovibrio, and 
Treponema [31].
Even in the same individual, there are differences between normal and disease 
tissue sites. One study compared cancerous tissue with matched healthy tissue, and 
the microbial diversity was significantly lower in tumor tissue, suggesting a more 
selective microenvironment in proximity to diseased tissue [32].
5. Clinical applications of microbiome analysis
Some studies stablish a relationship between the microbiota and the cancer 
therapy efficacy. Iida et al. showed that microbiota leads to enzyme expression 
required for optimal chemotherapy activity with oxaliplatin [18]. Guthrie et al. 
demonstrated that inhibition of microbial ß-glucuronidase increases the adverse 
effects of irinotecan in some patients [33]. Concerning immunotherapy, a great 
number of bacteria were observed having great clinical response to immune-
checkpoint therapy (by activating CTLA-4 and PD1 expression or promoting T-cell 
proliferation) [34].
Nevertheless, the main application nowadays is the fecal microbiota transplanta-
tion. This procedure consists in the administration of fecal bacteria from a healthy 
donor (without cancer, an autoimmune or metabolic disease) to a recipient by 
enema, colonoscopy, or enteric tube. The main objective is to alter the recipient’s 
microbiota composition, and it is performed in a variety of diseases like Clostridium 
difficile infection, irritable bowel syndrome, inflammatory bowel diseases, obesity, 
multiple sclerosis, and type 2 diabetes mellitus [35]. Unfortunately, the lack of evi-
dence and clinical trials bounds their use in clinical practice of oncologic patients.
Another potential application is through oral probiotics. Probiotics are supple-
ments with live bacteria that promote gut health. Some experimental models 
presented a reduction rate of colorectal cancer development with their consump-
tion [36].
6. Diet
Some dietary compounds may reach the colon by several reasons: they could be 
too large to be absorbed in the small intestine, they could escape the deglycosylation 
and absorption in the small intestine, and they could not be accessible to the host due 
to the mixture of food. The dietary compounds that are absorbed in the small intes-
tine could reach the colon by enterohepatic circulation [37]. Dietary bioactives can 
modify the carcinogenic process in several ways: by a direct or microbe-independent 
pathway and by an indirect or microbe-dependent pathway that include modifica-
tions in the substrates that alter the colonic microbiota or their metabolites [38]. The 
dietary fiber goes through the small intestine into the cecum and proximal colon 
where they are metabolized by the colonic microbiota and short-chain fatty acids are 
produced [39]. The most abundant short-chain fatty acids in the colon are acetate, 
propionate, and butyrate, and their concentrations typically decrease from the proxi-
mal to the distal colon [40]. The advantages from consuming fibers are the dilution 
of carcinogens and potential tumor promoters in the intestinal lumen [41] and the 
fast passage of the digesta through the colon which minimize the exposition to toxic 
products and increase the levels of short-chain fatty acids in the distal colon [42].
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Butyrate is the preferred substrate of colonocytes [43]. This compost was incred-
ibly studied due to its capacity to reduce oxidative stress, diminish inflammation 
and carcinogenesis, and support colonic barrier function [44].
The diet can shape the colonic microbiota and their function, and, on the other 
hand, the microbiota influences the health of the intestine. This way the host is 
protected from colon cancer and other inflammatory diseases.
7. Conclusions
CRC is the third most commonly diagnosed malignancy and the fourth leading 
cause of cancer death in the world. There are five CMS of CRC: the MSI-immune, 
the canonical subtype, the metabolic subtype, and the last subtype with mixed 
features. The strength of the in situ adaptive immune reaction is strongly correlated 
with time to recurrence and overall survival of CRC which leads us to think that 
the immune system plays an important role in CRC development. The consensus 
Immunoscore is a scoring system that outlines the density of CD3+ and CD8+ T-cell 
effectors existent in the tumor and its invasive margin, and the authors believe that 
this score could be a good prognostic marker. On the other hand, the dysbiosis could 
be combined with Immunoscore to increase the power of the biomarker. Studies 
about this interaction are needed. The role of microbiota in colorectal cancer is 
complex: its disturbance is the cause of tumorigenesis, or the outcome of tumor 
development is still uncertain.
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